Table 1.

Objective response rate

	Nivolumab plus ipilimumab (N=46)
All treated patients
Objective response rate (95% CI), %	17.4 (7.8 to 31.4)
Disease control rate (95% CI), %*	58.7 (43.2 to 73.0)
Best overall response, n (%)
Complete response	0
Partial response	8 (17.4)
Stable disease	19 (41.3)
Progressive disease	14 (30.4)
Not evaluable/available†	5 (10.9)
Patients with measurable tumor PD-L1 expression
Objective response rate (95% CI), %
PD-L1 ≥1%	12.5 (0.3 to 52.7)
PD-L1 <1%	14.3 (3.0 to 36.3)

*Proportion of patients with a best overall response of complete response, partial response, or stable disease.

†Patients were considered not evaluable or available if either no imaging/measurement was done at a specific time point or if only a subset of lesion measurements were done at an assessment.

PD-L1, programmed death ligand 1.